SUPN Biopharma · CNS drugs · ADHD · Parkinson's · Thesis updated July 19, 2026

New drugs must outrun old losses

Qelbree is the main engine, with Q1 2026 sales of $77.9 million, up 20% from a year earlier.
Adult Qelbree prescribers have now passed pediatric prescribers, a key sign that the bigger adult ADHD market is opening.
ONAPGO is back after supply trouble, with $8.4 million in Q1 2026 sales and about 2,200 enrollment forms through April 2026.
ZURZUVAE added $27.6 million of Q1 2026 collaboration revenue, giving Supernus a new growth lane in postpartum depression.
The biggest new worry is Qelbree patent litigation after a March 2026 challenge from Zydus Lifesciences.

01 Running thesis

A growth rebuild under legal pressure

Supernus is trying to replace fading older drugs with newer ones. The plan is working in pieces. Qelbree, GOCOVRI, ONAPGO, and ZURZUVAE all showed strength in Q1 2026, while older products like Trokendi XR, Oxtellar XR, and APOKYN kept shrinking.

The bull case starts with Qelbree. Q1 2026 sales were $77.9 million, up 20% from a year earlier, and adult prescribers passed pediatric prescribers for the first time. That matters because adult ADHD is the larger market and could make Qelbree more durable than a child-only drug.

ONAPGO also looks better than it did late in 2025. New patient starts resumed in February 2026 after supply limits, and the product posted $8.4 million of Q1 2026 sales. Management also expects to file for a second ONAPGO supplier in Q3 2026, with possible approval by mid-2027.

The bear case is not small. Qelbree is now under a Paragraph IV patent challenge from Zydus Lifesciences, which could bring generic risk earlier than investors expected. ONAPGO still depends on one main supplier until the second source is ready, and the Sage deal brought both ZURZUVAE upside and legal baggage.

May 2026→Q1 2026 strengthened the growth story, as Qelbree, GOCOVRI, ONAPGO, and ZURZUVAE all showed good demand. The same update added a major risk because Zydus Lifesciences challenged Qelbree patents.

Mar 2026→The 2025 Form 10-K showed that Sage acquisition costs drove a full-year net loss, while ONAPGO new patient starts had resumed in February 2026. The view stayed balanced because supply risk improved but did not go away.

Nov 2025▼ONAPGO demand was strong, but supplier constraints forced Supernus to pause delivery to patients who had not started therapy. ZURZUVAE added early revenue, but the supply issue hurt confidence in launch execution.

Aug 2025→The Sage Therapeutics deal added ZURZUVAE and a new postpartum depression growth path. It also raised integration risk and brought inherited legal and regulatory issues.

May 2025▲Qelbree growth continued to offset generic erosion in older products, and ONAPGO launched in April 2025. Supernus also planned a new SPN-820 Phase 2b trial in major depressive disorder.

Feb 2025→ONAPGO won FDA approval, creating a new commercial product. At the same time, SPN-820 failed a Phase 2b trial in treatment-resistant depression, making the story more dependent on marketed drugs.

Nov 2024▲Qelbree sales growth remained strong, and the FDA accepted the SPN-830 resubmission with a February 2025 target date. That created a clear near-term regulatory catalyst.

02 Business model

Selling a CNS drug basket

Supernus makes money mainly by selling approved medicines in the U.S. Its focus is central nervous system and related disorders, including ADHD, epilepsy, Parkinson's disease, and postpartum depression.

Qelbree is the biggest piece today. In Q1 2026 it made up about 37% of total revenue. GOCOVRI added another 17%, while ZURZUVAE collaboration revenue added about 13%. Supernus records ZURZUVAE collaboration revenue as 50% of the net revenues recorded by Biogen.

This model can work when newer branded drugs grow faster than older drugs lose sales. It breaks when patents, supply, or payor coverage get in the way. For Supernus, those are not abstract risks. Qelbree faces a patent suit, ONAPGO had supply limits, and ZURZUVAE still needs wide insurance coverage.

03 Product portfolio

The drugs that matter

Growth engine

Qelbree

Qelbree is the lead ADHD drug and the company's largest product. Q1 2026 sales were $77.9 million, up 20% from a year earlier.

Growth engine

ZURZUVAE

ZURZUVAE is an oral medicine for postpartum depression in adults. Supernus gained it through the Sage Therapeutics acquisition and recorded $27.6 million of Q1 2026 collaboration revenue.

Steady

GOCOVRI

GOCOVRI treats Parkinson's disease related movement issues. Q1 2026 sales were $35.2 million, up 15% from a year earlier.

Growth engine

ONAPGO

ONAPGO is a subcutaneous apomorphine infusion device for advanced Parkinson's disease. It had $8.4 million of Q1 2026 sales after new patient starts resumed in February 2026.

Cash cow

Trokendi XR, Oxtellar XR, and APOKYN

These older products are now in decline. Trokendi XR and Oxtellar XR face generic competition, while APOKYN is hurt by lower volume.

Option

SPN-820

SPN-820 remains a pipeline option, not a proven growth driver. A Phase 2b study in treatment-resistant depression failed, but Supernus later planned a new Phase 2b trial in major depressive disorder.

04 Business segments

Q1 2026 revenue mix

Qelbree37%growing fast

GOCOVRI17%modest

ZURZUVAE collaboration revenue13%growing fast

ONAPGO4%growing fast

Legacy and other revenue29%declining

Supernus reports as one operating segment. The mix below uses Q1 2026 product and collaboration revenue disclosures, with legacy and other revenue as the remainder of total revenue of $207.7 million.

05 Risk factors

What could break the thesis

Qelbree patent loss

High impact · Medium odds

Qelbree is the largest product and a main growth driver. In March 2026, Zydus Lifesciences sent a Paragraph IV notice challenging three Qelbree patents, and Supernus sued in April 2026. A bad court outcome or weak settlement could pull generic competition forward.

We watchCourt filings, settlement terms, and any update on Zydus Lifesciences in Qelbree patent litigation.

ONAPGO supply breaks again

High impact · Medium odds

ONAPGO demand already exceeded supply once, which forced Supernus to pause delivery to patients who had not started therapy. New patient starts resumed in February 2026, but the company still relies on one main supplier until a second source is approved. Management expects to file for that second supplier in Q3 2026, with possible approval by mid-2027.

We watchQ2 and Q3 2026 ONAPGO sales, new patient starts, and the Q3 2026 FDA submission for the second supplier.

Legacy erosion outruns new launches

Medium impact · High odds

Trokendi XR, Oxtellar XR, and APOKYN are shrinking because of generic competition and lower volumes. That creates a drag every quarter. Qelbree, GOCOVRI, ONAPGO, and ZURZUVAE need to grow enough to cover the hole.

We watchTotal revenue growth versus the decline in Trokendi XR, Oxtellar XR, and APOKYN.

ZURZUVAE access disappoints

Medium impact · Medium odds

ZURZUVAE has a clear medical story as an oral postpartum depression drug, but sales still depend on doctors prescribing it and insurers paying for it. If payors add strict rules or patients face high costs, the ramp could slow. A direct-to-consumer campaign may help, but it still has to turn awareness into prescriptions.

We watchZURZUVAE collaboration revenue, Biogen reported U.S. sales, payor coverage comments, and prescription trends after the DTC campaign.

Sage legal baggage

Medium impact · Medium odds

The Sage acquisition added ZURZUVAE, but it also brought inherited shareholder litigation and an SEC investigation tied to the zuranolone new drug application. The cost and outcome are uncertain. These issues can distract management and pressure cash if damages or penalties are large.

We watchUpdates on Sage shareholder lawsuits, the federal securities class action, and the SEC investigation.

06 Quick answers

In one breath

What does Supernus Pharmaceuticals do?

Supernus develops and sells medicines for central nervous system and related disorders. Its key areas include ADHD, Parkinson's disease, epilepsy, and postpartum depression.

What is Supernus's biggest product?

Qelbree is the biggest product in the Q1 2026 mix. It had $77.9 million of Q1 2026 sales, equal to about 37% of total revenue.

Why does ONAPGO matter for Supernus?

ONAPGO is a new Parkinson's disease launch that can help offset older product declines. It also carries supply risk because Supernus still needs a second supplier to reduce dependence on one source.

What is the main risk for SUPN stock?

The clearest risk is the Qelbree patent case because Qelbree is the largest growth driver. Other big risks are ONAPGO supply, ZURZUVAE coverage, and continued erosion in older drugs.